150 related articles for article (PubMed ID: 28638455)
1. The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy.
Jiang C; Liu S; He W; Zhang B; Xia L
J Cancer; 2017; 8(8):1410-1416. PubMed ID: 28638455
[No Abstract] [Full Text] [Related]
2. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer.
Yin C; Jiang C; Liao F; Rong Y; Cai X; Guo G; Qiu H; Chen X; Zhang B; He W; Xia L
Onco Targets Ther; 2014; 7():1415-22. PubMed ID: 25143746
[TBL] [Abstract][Full Text] [Related]
3. Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy.
Guo G; Chen X; Cai X; Chen Y; Wang H; Fan L; Bai L; Qiu H; Zhang B
Transl Cancer Res; 2019 Aug; 8(4):1137-1147. PubMed ID: 35116856
[TBL] [Abstract][Full Text] [Related]
4. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 as prognostic markers for advanced pancreatic cancer patients receiving first-line chemotherapy.
Shin K; Jung EK; Park SJ; Jeong S; Kim IH; Lee MA
World J Gastrointest Oncol; 2021 Aug; 13(8):915-928. PubMed ID: 34457195
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory indices as prognostic markers in metastatic colorectal cancer patients treated with chemotherapy plus Bevacizumab.
Passardi A; Azzali I; Bittoni A; Marisi G; Rebuzzi F; Molinari C; Bartolini G; Matteucci L; Sullo FG; Debonis SA; Gallio C; Monti M; Valgiusti M; Muratore M; Rapposelli IG; Ulivi P; Frassineti GL
Ther Adv Med Oncol; 2023; 15():17588359231212184. PubMed ID: 38107830
[TBL] [Abstract][Full Text] [Related]
7. CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
Narita Y; Taniguchi H; Komori A; Nitta S; Yamaguchi K; Kondo C; Nomura M; Kadowaki S; Takahari D; Ura T; Andoh M; Muro K
Cancer Chemother Pharmacol; 2014 Feb; 73(2):409-16. PubMed ID: 24322376
[TBL] [Abstract][Full Text] [Related]
8. Baseline serum lactate dehydrogenase level predicts survival benefit in patients with metastatic colorectal cancer receiving bevacizumab as first-line chemotherapy: a systematic review and meta-analysis of 7 studies and 1,219 patients.
Feng W; Wang Y; Zhu X
Ann Transl Med; 2019 Apr; 7(7):133. PubMed ID: 31157254
[TBL] [Abstract][Full Text] [Related]
9. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study.
Casadei-Gardini A; Scarpi E; Ulivi P; Palladino MA; Accettura C; Bernardini I; Spallanzani A; Gelsomino F; Corbelli J; Marisi G; Ruscelli S; Valgiusti M; Frassineti GL; Passardi A
Cancer Manag Res; 2019; 11():4357-4369. PubMed ID: 31191000
[No Abstract] [Full Text] [Related]
11. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer.
Matsuhashi N; Takahashi T; Fujii H; Suetsugu T; Fukada M; Iwata Y; Tokumaru Y; Imai T; Mori R; Tanahashi T; Matsui S; Imai H; Tanaka Y; Yamaguchi K; Futamura M; Yoshida K
Mol Clin Oncol; 2019 Oct; 11(4):390-396. PubMed ID: 31475067
[TBL] [Abstract][Full Text] [Related]
12. Impact of neutrophil-lymphocyte and platelet-lymphocyte ratio on antiEGFR and bevacizumab efficacy in metastatic colorectal cancer.
Dogan E; Bozkurt O; Sakalar T; Derin S; Inanc M; Ozkan M
J BUON; 2019; 24(5):1861-1869. PubMed ID: 31786848
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and predictive role of neutrophil/lymphocytes ratio in metastatic colorectal cancer: a retrospective analysis of the TRIBE study by GONO.
Dell'Aquila E; Cremolini C; Zeppola T; Lonardi S; Bergamo F; Masi G; Stellato M; Marmorino F; Schirripa M; Urbano F; Ronzoni M; Tomasello G; Zaniboni A; Racca P; Buonadonna A; Allegrini G; Fea E; Di Donato S; Chiara S; Tonini G; Tomcikova D; Boni L; Falcone A; Santini D
Ann Oncol; 2018 Apr; 29(4):924-930. PubMed ID: 29324972
[TBL] [Abstract][Full Text] [Related]
14. Impact of Pre-Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer.
Passardi A; Scarpi E; Tamberi S; Cavanna L; Tassinari D; Fontana A; Pini S; Bernardini I; Accettura C; Ulivi P; Frassineti GL; Amadori D
PLoS One; 2015; 10(8):e0134732. PubMed ID: 26244985
[TBL] [Abstract][Full Text] [Related]
15. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer.
Yin C; Ma G; Rong Y; Kong P; Yang Q; Jiang C; Liao F; Zhang B; He W; Xia L
J Cancer; 2016; 7(13):1901-1906. PubMed ID: 27698931
[No Abstract] [Full Text] [Related]
16. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data.
Guo G; Chen X; He W; Wang H; Wang Y; Hu P; Rong Y; Fan L; Xia L
PLoS One; 2018; 13(12):e0208547. PubMed ID: 30513126
[TBL] [Abstract][Full Text] [Related]
17. Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer.
Jiang C; Huang YH; Lu JB; Yang YZ; Rao HL; Zhang B; He WZ; Xia LP
Cancer Manag Res; 2018; 10():3589-3597. PubMed ID: 30271207
[TBL] [Abstract][Full Text] [Related]
18. Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis.
Quan Q; Huang Y; Chen Q; Qiu H; Hu Q; Rong Y; Li T; Xia L; Zhang B
Transl Oncol; 2017 Apr; 10(2):288-294. PubMed ID: 28292509
[TBL] [Abstract][Full Text] [Related]
19. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.
Marmorino F; Salvatore L; Barbara C; Allegrini G; Antonuzzo L; Masi G; Loupakis F; Borelli B; Chiara S; Banzi MC; Miraglio E; Amoroso D; Dargenio F; Bonetti A; Martignetti A; Paris M; Tomcikova D; Boni L; Falcone A; Cremolini C
Br J Cancer; 2017 Jan; 116(3):318-323. PubMed ID: 28081548
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Clarke SJ; Burge M; Feeney K; Gibbs P; Jones K; Marx G; Molloy MP; Price T; Reece WHH; Segelov E; Tebbutt NC
PLoS One; 2020; 15(3):e0229900. PubMed ID: 32142532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
